• TREATMENT

    Liposomal irinotecan, capecitabine, and bevacizumab show 8.1-month progression-free survival as second-line therapy

    In a multicenter study that enrolled 63 patients with metastatic colorectal cancer who had progressed on oxaliplatin-based first-line therapy, the combination achieved a 22.9% response rate and 89.6% disease control rate among the 48 patients who received at least one tumor assessment, with median overall survival of 19.5 months. (Cancer)